- Price
- $39.80
- Day
- -1.91%
- Mkt Cap
- $3.18B
- 52W Range
- $29.46 – $60.91
- Volume
- 2.67M
- Beta
- 1.93
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Squarepoint Ops LLC decreased its holdings in Veracyte, Inc. (NASDAQ: VCYT) by 76.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,853 shares of the biotechnology company's stock after selling 49,301 shares during the quarter. Squarepoint Ops LLC's holdings in
Read full article
Corient Private Wealth LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 26.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,021 shares of the biotechnology company's stock after acquiring an additional 34,299 shares during the
Read full article
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
Read full article
Concurrent Investment Advisors LLC bought a new position in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent filing with the SEC. The firm bought 17,644 shares of the biotechnology company's stock, valued at approximately $1,036,000. Several other hedge funds have also bought and sold shares of the business.
Read full article
On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
Read full article
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
Read full article
Canada Pension Plan Investment Board bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 20,700 shares of the biotechnology company's stock, valued at approximately $1,216,000. Several other hedge funds and
Read full article
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Read full article
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 26,948 shares of the biotechnology company's stock, valued at approximately $1,583,000. Other hedge funds and other institutional investors have also recently
Read full article